Blood Cancer’s First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

The FDA approved ropeginterferon alfa-2b (Besremi) injection to treat adults with essential thrombocythemia, the first new therapy for the chronic blood cancer since the 1997 approval of anagrelide.

A national survey showed that almost 40% of men 55 or older had never had a prostate-specific antigen (PSA) screening test for prostate cancer. (MedStar Health)

In a preliminary study, a blood test for early detection of lung cancer achieved 94% sensitivity and 97% negative predictive value. (Clinical Lab Products)

Patients receiving cancer treatment at Anne Arundel Medical Center in Maryland had to be rescheduled at other facilities after a cyberattack disrupted computer systems. (WBAL-TV 11)

Drug distributor and healthcare supply company McKesson acknowledged that unauthorized individuals stole data affecting customers in its oncology, multispecialty, and medical-surgical businesses.

Artificial intelligence can pick up breast cancers missed by mammography, but does it really make a difference? (UCLA Health)

Advances in risk stratification, new bladder-preserving treatment options, and new information about biomarkers and emerging therapies highlight an update to the American Urological Association/Society of Urologic Oncology clinical guideline for non-invasive bladder cancer.

A urine test for bladder cancer detected more than 90% of cancers in almost 1,000 patients referred for evaluation. (University of Birmingham)

Colon cancer in people 50 or younger has a different biology and survival compared with disease in older patients. (Medical Journal of Australia)

Patients with resectable non-small cell lung cancer (NSCLC) and a pathologic complete response after neoadjuvant therapy did not benefit from adjuvant immunotherapy. (Chinese Medical Journal)

The bispecific antibody ivonescimab led to better overall survival versus pembrolizumab (Keytruda) in a phase III study of patients with PD-L1-positive locally advanced/metastatic NSCLC, Summit Therapeutics announced.

AbbVie announced that the bispecific T-cell engager etentamig significantly improved response rate and progression-free survival versus standard therapy in a phase III trial of relapsed/refractory multiple myeloma.